Mark E Robson

List of Publications by Year in Descending Order

256 papers	24,035 citations	75 h-index	151 g-index
281 ext. papers	30,032 ext. citations	9.1 avg, IF	6.3 L-index

#	Paper	IF	Citations
256	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.. *Cell*, **2022**, 185, 563-575.e11	56.2	11
255	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. *JAMA Oncology*, **2022**,	13.4	5
254	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab.. *Npj Breast Cancer*, **2022**, 8, 37	7.8	0
253	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.. *Journal of Clinical Oncology*, **2022**, JCO2102767	2.2	7
252	The context-specific role of germline pathogenicity in tumorigenesis. *Nature Genetics*, **2021**, 53, 1577-1586	38.3	6
251	Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. *Pharmacogenetics and Genomics*, **2021**, 31, 1-9	1.9	
250	Germline RAD51B variants confer susceptibility to breast and ovarian cancers deficient in homologous recombination. *Npj Breast Cancer*, **2021**, 7, 135	7.8	0
249	Penetrance of male breast cancer susceptibility genes: a systematic review. *Breast Cancer Research and Treatment*, **2021**, 1	4.4	2
248	PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. *The Cochrane Library*, **2021**, 4, CD011395	5.2	6
247	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. *Gynecologic Oncology*, **2021**, 161, 521-526	4.9	1
246	Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer. *Cancer Medicine*, **2021**, 10, 5163-5174	4.8	5
245	Comprehensive Breast Cancer Risk Assessment for and Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. *JCO Precision Oncology*, **2021**, 5,	3.6	2
244	PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays. *American Journal of Surgical Pathology*, **2021**, 45, 1274-1281	6.7	2
243	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
242	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. *Cancer Discovery*, **2021**, 11, 2796-2811	24.4	10
241	Tolerability of Breast Radiotherapy Among Carriers of Germline Variants. *JCO Precision Oncology*, **2021**, 5,	3.6	1
240	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4

239	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. *Nature Cancer*, **2021**, 2, 357-365	15.4	23
238	Prevalence and Characterization of Biallelic and Monoallelic and Variant Carriers From a Pan-Cancer Patient Population. *JCO Precision Oncology*, **2021**, 5,	3.6	3
237	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. *Npj Breast Cancer*, **2021**, 7, 96	7.8	7
236	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
235	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. *Genetics in Medicine*, **2021**, 23, 2105-2113	8.1	2
234	Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than or. *Journal of Clinical Oncology*, **2021**, 39, 2528-2534	2.2	1
233	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. *Journal of the National Cancer Institute*, **2021**,	9.7	12
232	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. *Journal of Clinical Oncology*, **2021**, 39, 2698-2709	2.2	16
231	Oncology PatientsO Perspectives on Remote Patient Monitoring for COVID-19. *JCO Oncology Practice*, **2021**, 17, e1278-e1285	2.3	2
230	Protein-altering germline mutations implicate novel genes related to lung cancer development. *Nature Communications*, **2020**, 11, 2220	17.4	6
229	Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test. *Public Health Genomics*, **2020**, 23, 6-19	1.9	4
228	Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma. *Modern Pathology*, **2020**, 33, 2221-2232	9.8	10
227	Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 1275-1279	9.7	6
226	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
225	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
224	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. *Journal of Clinical Oncology*, **2020**, 38, 1398-1408	2.2	20
223	Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. *Journal of Clinical Oncology*, **2020**, 38, 2080-2106	2.2	95
222	Alterations in and promote clinical resistance to alpelisib plus aromatase inhibitors. *Nature Cancer*, **2020**, 1, 382-393	15.4	49

221	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
220	Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. *Clinical Cancer Research*, **2020**, 26, 3239-3247	12.9	58
219	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. *JCI Insight*, **2020**, 5,	9.9	7
218	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With /CEP17 Ratio . *Archives of Pathology and Laboratory Medicine*, **2020**, 144, 597-601	5	9
217	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
216	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. *Journal of Thoracic Oncology*, **2020**, 15, 655-660	8.9	14
215	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
214	The genomic landscape of metastatic histologic special types of invasive breast cancer. *Npj Breast Cancer*, **2020**, 6, 53	7.8	10
213	Yoga for Chemotherapy-Induced Peripheral Neuropathy and Fall Risk: A Randomized Controlled Trial. *JNCI Cancer Spectrum*, **2020**, 4, pkaa048	4.6	10
212	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
211	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. *JAMA Network Open*, **2020**, 3, e208501	10.4	38
210	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. *Nature Genetics*, **2020**, 52, 1219-1226	36.3	103
209	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. *Journal of Clinical Oncology*, **2020**, 38, 4274-4282	2.2	92
208	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
207	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. *Human Mutation*, **2020**, 41, 103-109	4.7	11
206	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. *European Journal of Cancer*, **2019**, 120, 20-30	7.5	35
205	Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening Wider. *JAMA Oncology*, **2019**,	13.4	13
204	Pilot study of rapid MR pancreas screening for patients with BRCA mutation. *European Radiology*, **2019**, 29, 3976-3985	8	5

203	Differences between screen-detected and interval breast cancers among BRCA mutation carriers. *Breast Cancer Research and Treatment*, **2019**, 175, 141-148	4.4	5
202	OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician© choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. *Annals of Oncology*, **2019**, 30, 558-566	10.3	240
201	RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. *Journal of the National Cancer Institute*, **2019**, 111, 522-523	9.7	5
200	The Landscape of Somatic Genetic Alterations in Breast Cancers from Germline Mutation Carriers. *JNCI Cancer Spectrum*, **2019**, 3, pkz027	4.6	7
199	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
198	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. *Breast Cancer Research and Treatment*, **2019**, 177, 61-66	4.4	23
197	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. *Journal of Medical Genetics*, **2019**, 56, 347-357	5.8	19
196	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *Journal of Clinical Oncology*, **2019**, 37, 286-295	2.2	203
195	Homologous recombination DNA repair defects in associated breast cancers. *Npj Breast Cancer*, **2019**, 5, 23	7.8	20
194	Tumour lineage shapes BRCA-mediated phenotypes. *Nature*, **2019**, 571, 576-579	50.4	170
193	Health outcomes, utility and costs of returning incidental results from genomic sequencing in a Canadian cancer population: protocol for a mixed-methods randomised controlled trial. *BMJ Open*, **2019**, 9, e031092	3	5
192	Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	2
191	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. *Nature Medicine*, **2019**, 25, 1928-1937	50.5	263
190	Endometrial Cancers in or Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. *JCO Precision Oncology*, **2019**, 3,	3.6	14
189	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline Mutations (ABRAZO). *Clinical Cancer Research*, **2019**, 25, 2717-2724	12.9	65
188	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
187	Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 219-227	6.1	4
186	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22

185	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2018**, 110, 1030-1034	9.7	65
184	A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. *Genetics in Medicine*, **2018**, 20, 1324-1327	8.1	20
183	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. *Journal of the National Cancer Institute*, **2018**, 110, 1067-1074	9.7	103
182	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
181	Genome doubling shapes the evolution and prognosis of advanced cancers. *Nature Genetics*, **2018**, 50, 1189-1195	36.3	208
180	A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients. *European Journal of Cancer*, **2018**, 101, 12-19	7.5	39
179	Germline mutations in children and adults with cancer. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	20
178	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. *Breast Cancer Research and Treatment*, **2018**, 172, 487-496	4.4	20
177	A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer. *Case Reports in Oncological Medicine*, **2018**, 2018, 9529821	0.9	2
176	Moderate-Penetrance Predisposition to Breast Cancer. *Current Breast Cancer Reports*, **2018**, 10, 232-239	0.8	
175	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. *Journal of Clinical Oncology*, **2018**, 36, 1504-1504	2.2	2
174	Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. *Breast Cancer Research and Treatment*, **2018**, 168, 543-550	4.4	5
173	Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women© Environmental Cancer and Radiation Epidemiology Study. *Journal of Clinical Oncology*, **2018**, 36, 1513-1520	2.2	29
172	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. *Journal of Clinical Oncology*, **2018**, 36, 414-424	2.2	107
171	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90
170	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. *Cancer Cell*, **2018**, 34, 427-438	24.5	339
169	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. *JAMA Oncology*, **2018**, 4, 1228-1235	13.4	66
168	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. *Breast Cancer Research and Treatment*, **2017**, 162, 297-306	4.4	12

167	SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. *Breast Cancer Research and Treatment*, **2017**, 164, 189-199	4.4	13
166	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nature Medicine*, **2017**, 23, 703-713	50.5	1638
165	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	22
164	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
163	Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. *New England Journal of Medicine*, **2017**, 377, 523-533	59.2	1405
162	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2017**, 163, 565-571	4.4	53
161	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
160	Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer. *New England Journal of Medicine*, **2017**, 377, 1792-3	59.2	39
159	Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. *European Journal of Radiology*, **2017**, 97, 37-43	4.7	66
158	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. *JCO Precision Oncology*, **2017**, 2017,	3.6	151
157	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. *Journal of Clinical Oncology*, **2017**, 35, 1262-1263	2.2	1
156	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
155	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 825-835	27.4	235
154	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncology*, **2017**, 3, 1634-1639	13.4	107
153	Diverse and Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. *Clinical Cancer Research*, **2017**, 23, 6708-6720	12.9	132
152	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. *Cell Stem Cell*, **2017**, 21, 374-382.e4	18	339
151	Germline mutations detected in pediatric sequencing studies impact parents' evaluation and care. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	13
150	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. *BMC Medical Genomics*, **2017**, 10, 33	3.7	64

149	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
148	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. *Future Oncology*, **2017**, 13, 307-320	3.6	30
147	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. *Journal of Genetic Counseling*, **2017**, 26, 232-243	2.5	8
146	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
145	The Role of Genetic Counseling in Familial and Sporadic Cancer: Considerations, Challenges, and Collaboration. *Annals of Internal Medicine*, **2017**, 167, 884-885	8	2
144	Identification and Functional Characterization of V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. *JCO Precision Oncology*, **2017**, 1,	3.6	7
143	Decision-Making Preferences About Secondary Germline Findings That Arise From Tumor Genomic Profiling Among Patients With Advanced Cancers. *JCO Precision Oncology*, **2017**, 1,	3.6	4
142	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
141	Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family. *Breast Cancer Research and Treatment*, **2016**, 160, 447-456	4.4	12
140	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*, **2016**, 34, 2750-60	2.2	107
139	Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nature Reviews Clinical Oncology*, **2016**, 13, 581-8	19.4	200
138	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. *JAMA Oncology*, **2016**, 2, 104-11	13.4	198
137	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
136	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncology*, **2016**, 2, 1434-1440	13.4	151
135	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
134	Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. *Cancer*, **2016**, 122, 1178-84	6.4	29
133	Response. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	2
132	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. *ESMO Open*, **2016**, 1, e000097	6	59

131	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. *Journal of Clinical Oncology*, **2016**, 34, 2141-7	2.2	170
130	Genetic Testing Awareness and Attitudes among Latinos: Exploring Shared Perceptions and Gender-Based Differences. *Public Health Genomics*, **2016**, 19, 34-46	1.9	26
129	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
128	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
127	Population Frequency of Germline BRCA1/2 Mutations. *Journal of Clinical Oncology*, **2016**, 34, 4183-4185	2.2	64
126	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
125	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
124	Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. *Steroids*, **2015**, 99, 32-8	2.8	32
123	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
122	Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. *Nature Reviews Clinical Oncology*, **2015**, 12, 505-6	19.4	3
121	American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *Journal of Clinical Oncology*, **2015**, 33, 3660-7	2.2	360
120	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
119	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
118	Identification of germline genetic mutations in patients with pancreatic cancer. *Cancer*, **2015**, 121, 4382-8	6.4	117
117	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
116	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
115	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587
114	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. *Blood*, **2015**, 126, 2447-2447	2.2	

113	A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. *Clinical Breast Cancer*, **2014**, 14, 154-60	3	75
112	Cancer genomics and inherited risk. *Journal of Clinical Oncology*, **2014**, 32, 687-98	2.2	100
111	Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. *BMC Medicine*, **2014**, 12, 140	11.4	30
110	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. *Breast Cancer Research and Treatment*, **2014**, 145, 625-34	4.4	7
109	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. *Familial Cancer*, **2014** , 13, 459-67	3	12
108	Germline EGFR T790M mutation found in multiple members of a familial cohort. *Journal of Thoracic Oncology*, **2014**, 9, 554-8	8.9	47
107	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
106	Understanding the Paradigm Challenges Posed by Multiplex Panel Testing for Cancer Susceptibility. *Current Genetic Medicine Reports*, **2014**, 2, 250-254	2.2	
105	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
104	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
103	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30
102	Revealing the incidentalome when targeting the tumor genome. *JAMA - Journal of the American Medical Association*, **2013**, 310, 795-6	27.4	51
101	Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. *European Journal of Cancer*, **2013**, 49, 2979-85	7.5	51
100	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
99	Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. *Breast Cancer Research and Treatment*, **2013**, 139, 497-506	4.4	18
98	Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. *Science Translational Medicine*, **2013**, 5, 172ra21	17.5	290
97	Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. *Breast Cancer Research and Treatment*, **2013**, 138, 273-9	4.4	25
96	Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. *Annals of Surgical Oncology*, **2013**, 20, 3469-76	3.1	95

95	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
94	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
93	Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. *PLoS Genetics*, **2013**, 9, e1003220	6	38
92	Genetic Epidemiology of Breast Cancer **2013**, 1113-1125		
91	TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. *Molecular Endocrinology*, **2013**, 27, 657-70		42
90	Multiplex genetic testing for cancer susceptibility: out on the high wire without a net?. *Journal of Clinical Oncology*, **2013**, 31, 1267-70	2.2	184
89	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. *Cancer*, **2013**, 119, 1344-8	6.4	37
88	Assessment of SLX4 Mutations in Hereditary Breast Cancers. *PLoS ONE*, **2013**, 8, e66961	3.7	24
87	Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. *BJU International*, **2012**, 109, 713-9	5.6	31
86	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. *Cancer*, **2012**, 118, 493-9	6.4	71
85	Screening for germline EGFR T790M mutations through lung cancer genotyping. *Journal of Thoracic Oncology*, **2012**, 7, 1049-52	8.9	92
84	Rare de novo germline copy-number variation in testicular cancer. *American Journal of Human Genetics*, **2012**, 91, 379-83	11	20
83	Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. *Cancer*, **2012**, 118, 4944-52	6.4	49
82	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. *Breast Cancer Research and Treatment*, **2012**, 133, 1125-30	4.4	120
81	What women with breast cancer discuss with clinicians about risk for their adolescent daughters. *Journal of Psychosocial Oncology*, **2012**, 30, 484-502	2.8	8
80	Risks to relatives in genomic research: a duty to warn?. *American Journal of Bioethics*, **2012**, 12, 12-4	1.1	17
79	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
78	Juvenile polyposis syndrome presenting with familial gastric cancer and massive gastric polyposis. *Journal of Clinical Oncology*, **2012**, 30, e229-32	2.2	7

77	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
76	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
75	Germline PALB2 mutation analysis in breast-pancreas cancer families. *Journal of Medical Genetics*, **2011**, 48, 523-5	5.8	24
74	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
73	Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. *Patient Education and Counseling*, **2011**, 83, 92-8	3.1	58
72	Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2-associated breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 4224-6	2.2	21
71	An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. *Oncologist*, **2011**, 16, 1397-402	5.7	190
70	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
69	A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. *Clinical Cancer Research*, **2011**, 17, 3398-407	12.9	28
68	American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *Journal of Clinical Oncology*, **2010**, 28, 893-901	2.2	349
67	Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. *Cancer Research*, **2010**, 70, 3278-86	10.1	58
66	Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. *Journal of Clinical Oncology*, **2010**, 28, 628-33	2.2	41
65	New pharmacogenomic paradigm in breast cancer treatment. *Journal of Clinical Oncology*, **2010**, 28, 4665-6	2.2	13
64	Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. *Clinical Cancer Research*, **2010**, 16, 2115-21	12.9	196
63	Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. *Clinical Cancer Research*, **2010**, 16, 755-63	12.9	69
62	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. *Lancet, The*, **2010**, 376, 235-44	40	1395
61	Genome-wide association studies of cancer predisposition. *Hematology/Oncology Clinics of North America*, **2010**, 24, 973-96	3.1	33
60	Genome-wide association studies of cancer. *Journal of Clinical Oncology*, **2010**, 28, 4255-67	2.2	127

59	Inherited predisposition to cancer: introduction and overview. *Hematology/Oncology Clinics of North America*, **2010**, 24, 793-7	3.1	5
58	Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. *Cancer Journal (Sudbury, Mass)*, **2010**, 16, 48-52	2.2	38
57	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. *Breast Cancer Research and Treatment*, **2010**, 123, 581-5	4.4	15
56	Genetic analysis of the early natural history of epithelial ovarian carcinoma. *PLoS ONE*, **2010**, 5, e10358	3.7	74
55	The 6q22.33 locus and breast cancer susceptibility. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2468-75	4	22
54	BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. *Journal of Clinical Oncology*, **2009**, 27, 433-8	2.2	160
53	American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. *Journal of Clinical Oncology*, **2009**, 27, 986-93	2.2	50
52	Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. *Journal of the National Cancer Institute*, **2009**, 101, 205-9	9.7	94
51	Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. *Human Mutation*, **2009**, 30, 1543-50	4.7	24
50	Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. *Breast Cancer Research and Treatment*, **2009**, 114, 127-35	4.4	23
49	Inherited predisposition to gastrointestinal stromal tumor. *Hematology/Oncology Clinics of North America*, **2009**, 23, 1-13, vii	3.1	36
48	Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. *Clinical Breast Cancer*, **2008**, 8, 418-24	3	8
47	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *Journal of Clinical Oncology*, **2008**, 26, 1331-7	2.2	465
46	The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 1216-22	2.2	51
45	Clinical practice. Management of an inherited predisposition to breast cancer. *New England Journal of Medicine*, **2007**, 357, 154-62	59.2	194
44	Adjuvant treatment recommendations in older women with breast cancer: a survey of oncologists. *Critical Reviews in Oncology/Hematology*, **2007**, 61, 255-60	7	27
43	Protecting the privacy of third-party information: recommendations for social and behavioral health researchers. *Social Science and Medicine*, **2007**, 64, 213-22	5.1	10
42	Treatment of hereditary breast cancer. *Seminars in Oncology*, **2007**, 34, 384-91	5.5	12

41	Seizing the Opportunity: Recognition and Management of Hereditary Cancer Predisposition. *Seminars in Oncology*, **2007**, 34, 367-368	5.5	2
40	Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. *Annals of Surgical Oncology*, **2007**, 14, 2510-8	3.1	72
39	Is breast conservation a reasonable option for women with BRCA-associated breast cancer?. *Nature Clinical Practice Oncology*, **2007**, 4, 10-1		2
38	BRCA mutations in women with ductal carcinoma in situ. *Clinical Cancer Research*, **2007**, 13, 4306-10	12.9	26
37	Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. *Clinical Cancer Research*, **2007**, 13, 223-7	12.9	10
36	Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 2311-3	4	51
35	A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. *Journal of the American Geriatrics Society*, **2006**, 54, 1119-24	5.6	76
34	Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient© perspective. *Breast Cancer Research and Treatment*, **2006**, 98, 343-8	4.4	71
33	Evaluation of germline PTEN mutations in endometrial cancer patients. *Gynecologic Oncology*, **2005** , 96, 21-4	4.9	32
32	Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. *Cancer*, **2005**, 103, 44-51	6.4	123
31	Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. *Cancer*, **2005**, 104, 314-20	6.4	23
30	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. *Familial Cancer*, **2005**, 4, 177-81	3	28
29	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. *Journal of the National Cancer Institute*, **2005**, 97, 1382-4	9.7	70
28	A comparison of bilateral breast cancers in BRCA carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2005**, 14, 1534-8	4	42
27	The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriersK.A. Metcalfe, H.T. Lynch, P. Ghadirian, N. Tung, I.A. Olivotto, W.D. Foulkes, E. Warner, O. Olopade, A. Eisen, B. Weber, et al. Gynecol Oncol 2005;96:222–6. *Womenls Oncology Review*, **2005**, 5, 163-164		
26	Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. *Clinical Cancer Research*, **2004**, 10, 5754-61	12.9	29
25	BRCA mutations and risk of prostate cancer in Ashkenazi Jews. *Clinical Cancer Research*, **2004**, 10, 2918-21	12.9	139
24	Breast MRI for women with hereditary cancer risk. *JAMA - Journal of the American Medical Association*, **2004**, 292, 1368-70	27.4	33

23	Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. *Clinical Cancer Research*, **2004**, 10, 1250-4	12.9	91
22	Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. *Cancer Research*, **2004**, 64, 5051-3	10.1	42
21	Hereditary ovarian cancer in Ashkenazi Jews. *Familial Cancer*, **2004**, 3, 259-64	3	31
20	Breast cancer surveillance in women with hereditary risk due to BRCA1 or BRCA2 mutations. *Clinical Breast Cancer*, **2004**, 5, 260-8; discussion 269-71	3	23
19	A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. *Breast Cancer Research*, **2004**, 6, R8-R17	8.3	225
18	Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. *Journal of Clinical Oncology*, **2003**, 21, 4222-7	2.2	169
17	Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *Journal of the National Cancer Institute*, **2003**, 95, 1548-51	9.7	160
16	Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. *Gynecologic Oncology*, **2003**, 89, 281-7	4.9	111
15	Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. *Gynecologic Oncology*, **2003**, 89, 440-6	4.9	35
14	Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. *Cancer* , **2003**, 97, 1601-8	6.4	79
13	Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. *Cancer*, **2003**, 98, 2170-6	6.4	35
12	Frequency of CHEK2*1100delC in New York breast cancer cases and controls. *BMC Medical Genetics* , **2003**, 4, 1	2.1	91
11	Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. *Cancer Control*, **2002**, 9, 457-65	2.2	33
10	Considerations in genetic counseling for inherited breast cancer predisposition. *Seminars in Radiation Oncology*, **2002**, 12, 362-70	5.5	
9	Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. *Oncogene*, **2002**, 21, 7034-41	9.2	34
8	Estrogen receptor-beta expression in hereditary breast cancer. *Journal of Clinical Oncology*, **2002**, 20, 3752-3; author reply 3753	2.2	18
7	Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2002**, 94, 1773-9	9.7	266
6	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *New England Journal of Medicine*, **2002**, 346, 1609-15	59.2	1198

5	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. *Genetics in Medicine*, **2001**, 3, 422-5	8.1	16
4	Risk of endometrial carcinoma associated with BRCA mutation. *Gynecologic Oncology*, **2001**, 80, 395-8	4.9	135
3	Hereditary breast cancer. *Current Problems in Surgery*, **2001**, 38, 387-480	2.8	111
2	Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. *Cancer*, **2000**, 89, 383-90	6.4	90
1	Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. *Lancet, The*, **2000**, 356, 1876-81	40	473